Navigation Links
WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
Date:5/6/2008

SHANGHAI, China, May 6 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has postponed its proposed underwritten follow-on public offering.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

''In light of market conditions and the current trading price for our ADSs, our board has determined it is in the best interest of our shareholders to postpone the offering,'' said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. A copy of the registration statement for this offering may be obtained at http://www.sec.gov . These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .

For more information, please contact:

Investor Contact:

Dr. Hai Mi, Vice President,

Corporate Communications

WuXi PharmaTech (Cayman) Inc.

Tel: +86-21-5046-3726

Email: ir@pharmatechs.com

Web: http://www.wuxipharmatech.com

Investor Relations (US):

Mahmoud Siddig, Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: pharmatechs@taylor-rafferty.com

Web: http://www.taylor-rafferty.com

Investor Relations (HK):

Ruby Yim, Managing Director

Taylor Rafferty

Tel: +852-3196-3712

Email: pharmatechs@taylor-rafferty.com

Web: http://www.taylor-rafferty.com

Media Contact:

John Dudzinsky, Director

Taylor Rafferty

Tel: +1-212-889-4350

Email: pharmatechs@taylor-rafferty.com

Web: http://www.taylor-rafferty.com


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Princeton Professor David W. C. MacMillan Lectured WuXi PharmaTech Scientists
2. WuXi PharmaTech (NYSE: WX) Names Temporary Chairman of the Audit Committee
3. WuXi PharmaTech (NYSE: WX) Mourns the Tragic Loss of Its Independent Director Shawn Wang
4. WestChina-Frontier PharmaTech Awarded Full AAALAC Accreditation
5. WuXi PharmaTech Announces Third Quarter 2007 Results
6. WuXi PharmaTech (NYSE: WX) CEO Honored with Ernst & Young Entrepreneur Of The Year China 2007 Award
7. WuXi PharmaTech Schedules 2007 Third Quarter Earnings Release on Monday, November 12, 2007
8. Rigel Announces First Quarter 2008 Financial Results
9. BioForm Medical Announces Extension of Lock-Up Period
10. Healthcare Realty Trust Announces First Quarter Results
11. WWMR, Inc. Announces New Website to Showcase Research Case Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... The International ... 7th annual “Imagine Me Beyond What You See” body image mannequin art competition. Selected ... will be showcased and the winner revealed at the 31st annual iaedp Symposium, March ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle Farms, ... their Military Wedding Giveaway, with the winning couple announced on Feb. 14, 2017, ... generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, A ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... 23, 2017 , ... EBSCO Information Services (EBSCO) ... for Health and Care Excellence (NICE) framework. The agreement allows purchasers from ... to search, order and purchase medical and healthcare-related content through GOBI ®, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... today that it will soon begin franchising throughout the U.S. starting this spring. ... help bring the practice of meditation mainstream. Current Meditation will be the first ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australie, le 24 février 2017 ITL Limited, ( ... diversifiée innovante, est ravie d,annoncer les excellents résultats semestriels ... période précédente correspondante. Une présentation complète « Résultats et mise ... consultée ici . Faits marquants ... 2,12 millions $ (Déc. 2015 : 1,04 million $ ; en hausse de 104 %) ...
(Date:2/24/2017)... 23, 2017 Non-alcoholic steatohepataitis (NASH) ... various drugs being developed for the treatment ... drugs that are in various phases of ... focuses on novel pharmacologic drugs & regenerative ... therapies, recombinant proteins and RNA-based therapeutics, but ...
(Date:2/24/2017)... 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology drug ... has acquired exclusive worldwide rights to develop, manufacture ... inhibitor targeting hematological and solid tumors. ... and 2 clinical trials of Abexinostat in US, ... already been completed, demonstrating that Abexinostat is clinically ...
Breaking Medicine Technology: